Navigating Lymphedema: The Impact of Indocyanine Green Lymphography on Personalized Therapy Outcomes in Breast Cancer Patients.

IF 2.9 3区医学 Q2 ONCOLOGY Clinical breast cancer Pub Date : 2024-10-18 DOI:10.1016/j.clbc.2024.10.010

Atilla Soran, Kazim Senol, Kristin Lupinacci

{"title":"Navigating Lymphedema: The Impact of Indocyanine Green Lymphography on Personalized Therapy Outcomes in Breast Cancer Patients.","authors":"Atilla Soran, Kazim Senol, Kristin Lupinacci","doi":"10.1016/j.clbc.2024.10.010","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the role of Indocyanine Green Lymphography (ICG_L) in the early diagnosis and personalized management of breast cancer-related lymphedema (BCRL) among high-risk breast cancer (BC) survivors.Methods: Patients who admitted to the UPMC Magee-Womens Hospital Lymphedema Program between October 2018 and December 2021 with episodic symptoms were enrolled into the study. Patient demographics, clinical characteristics, and outcomes were prospectively collected and retrospectively analysed. Lymphatic flow disruptions were identified and guided personalized therapeutic interventions were guided by ICG_L.Results: Among 154 BC survivors, 184 arms were evaluated. Initial ICG_L showed 57.1% had no lymphedema, while 42.9% were classified as stage 1 to 3 lymphedema. Early diagnosis and personalized interventions provided improved outcomes, with only 4.3% developing clinical lymphedema after a median follow-up of 27 months. Patients exhibited stable or improved symptoms with individualized treatments such as manual lymphatic drainage, compression therapies, and physiotherapy.Conclusion: ICG_L evaluation is essential for patients at high-risk of developing BCRL. Early diagnosis before clinical onset of lymphedema, and ICG_L guided therapy significantly enhances the clinical outcomes and improves lymphedema management.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2024.10.010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the role of Indocyanine Green Lymphography (ICG_L) in the early diagnosis and personalized management of breast cancer-related lymphedema (BCRL) among high-risk breast cancer (BC) survivors.

Methods: Patients who admitted to the UPMC Magee-Womens Hospital Lymphedema Program between October 2018 and December 2021 with episodic symptoms were enrolled into the study. Patient demographics, clinical characteristics, and outcomes were prospectively collected and retrospectively analysed. Lymphatic flow disruptions were identified and guided personalized therapeutic interventions were guided by ICG_L.

Results: Among 154 BC survivors, 184 arms were evaluated. Initial ICG_L showed 57.1% had no lymphedema, while 42.9% were classified as stage 1 to 3 lymphedema. Early diagnosis and personalized interventions provided improved outcomes, with only 4.3% developing clinical lymphedema after a median follow-up of 27 months. Patients exhibited stable or improved symptoms with individualized treatments such as manual lymphatic drainage, compression therapies, and physiotherapy.

Conclusion: ICG_L evaluation is essential for patients at high-risk of developing BCRL. Early diagnosis before clinical onset of lymphedema, and ICG_L guided therapy significantly enhances the clinical outcomes and improves lymphedema management.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

为淋巴水肿导航：吲哚菁绿淋巴造影对乳腺癌患者个性化治疗结果的影响。

目的：评估吲哚菁绿淋巴造影术（ICG_L）在高危乳腺癌（BC）幸存者乳腺癌相关淋巴水肿（BCRL）的早期诊断和个性化管理中的作用：在2018年10月至2021年12月期间，UPMC马吉-妇科医院淋巴水肿项目收治的有偶发症状的患者被纳入研究。对患者的人口统计学特征、临床特征和结果进行了前瞻性收集和回顾性分析。通过ICG_L确定淋巴流动障碍，并指导个性化治疗干预：结果：在 154 名 BC 幸存者中，对 184 条手臂进行了评估。初步ICG_L显示，57.1%的人没有淋巴水肿，42.9%的人被归类为淋巴水肿1至3期。早期诊断和个性化干预改善了治疗效果，在中位随访27个月后，仅有4.3%的患者出现临床淋巴水肿。患者在接受人工淋巴引流、压力疗法和物理疗法等个性化治疗后，症状得到稳定或改善：结论：ICG_L 评估对于 BCRL 高危患者至关重要。结论：ICG_L 评估对 BCRL 高危患者至关重要，在淋巴水肿临床发作前进行早期诊断，并在 ICG_L 指导下进行治疗，可显著提高临床疗效，改善淋巴水肿管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.